Temsirolimus in Combination with Bendamustine and Rituximab (BeRT) for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Final Phase I/II Results

被引：3
|
作者：
Hess, Georg [1 ]
Karola, Wagner [2 ]
LaRosee, Paul [3 ]
Keller, Ulrich [4 ]
Atta, Johannes [5 ]
Witzens-Harig, Mathias [6 ]
Crombe, Anne [7 ]
Medler, Christoph [8 ]
Borchmann, Peter [9 ,10 ]
Bitz, Ulrich [11 ]
Lerchenmuller, Christian [12 ]
Theobald, Matthias [1 ]
Dreyling, Martin H. [13 ]
机构：
[1] Johannes Gutenberg Univ Med Ctr, III Dept Med, Mainz, Germany
[2] Charite, Gerlingen, Germany
[3] Jena Univ Hosp, Jena, Germany
[4] Tech Univ Munich, Munich, Germany
[5] Goethe Univ Frankfurt, Frankfurt, Germany
[6] Univ Heidelberg Hosp, Dept Internal Med V, Heidelberg, Germany
[7] Univ Mainz Hosp, Interdisciplinary Ctr Clin Trials IZKS, Mainz, Germany
[8] IZKS, Mainz, Germany
[9] Univ Hosp Cologne, Dept I Internal Med, Cologne, Germany
[10] Univ Hosp Cologne, German Hodgkin Study Grp GHSG, Cologne, Germany
[11] HELIOS Klin Bad Saarow, Bad Saarow Pieskow, Germany
[12] Outpatient Clin, Hematol & Oncol, Munster, Germany
[13] Univ Hosp Grosshadern LMU, Dept Med III, Munich, Germany
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.2977.2977
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2977
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study
    Flowers, Christopher R.
    Matasar, Matthew J.
    Herrera, Alex F.
    Hertzberg, Mark
    Assouline, Sarit
    Demeter, Judit
    Mcmillan, Andrew
    Mehta, Amitkumar
    Opat, Stephen
    Trneny, Marek
    Musick, Lisa
    Hirata, Jamie
    Yang, Annie
    Sehn, Laurie H.
    REVISTA CHILENA DE LITERATURA, 2024, (109): : 1194 - 1205
  • [42] Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study
    Flowers, Christopher R.
    Matasar, Matthew J.
    Herrera, Alex F.
    Hertzberg, Mark
    Assouline, Sarit
    Demeter, Judit
    Mcmillan, Andrew
    Mehta, Amitkumar
    Opat, Stephen
    Trneny, Marek
    Musick, Lisa
    Hirata, Jamie
    Yang, Annie
    Sehn, Laurie H.
    HAEMATOLOGICA, 2024, 109 (04) : 1194 - 1205
  • [43] Lenalidomide and Rituximab Are a Promising Combination in Vitro, in Vivo Preclinically and in a Phase I/II Clinical Trial in Relapsed/Refractory Mantle Cell Lymphoma
    Wang, Michael
    Zhang, Liang
    Fayad, Luis
    Hagemeister, Fredrick
    Neelapu, Sattva
    Samaniego, Felipe
    Pro, Barbara
    Younes, Anas
    Miller, Scott
    Knight, Robert D.
    Zeldis, Jerome B.
    Yi, Qing
    Romaguera, Jorge
    BLOOD, 2008, 112 (11) : 1051 - 1051
  • [44] Phase II: Combination of cladribine, cyclophosphamide, mitoxantrone, rituximab (R-CCM) in patients with relapsed and refractory follicular and mantle cell lymphoma, results of a prospective study at Kitasato University
    Suzuki, Y.
    Danbara, M.
    Hayama, M.
    Togano, T.
    Ohsaka, M.
    Miyazaki, K.
    Horie, R.
    Higashihara, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [45] Treatment of Synchronous Mantle Cell Lymphoma and Small Lymphocytic Lymphoma with Bendamustine and Rituximab
    Kourelis, Taxiarchis V.
    Kahl, Brad S.
    Benn, Peter
    Delach, Judith A.
    Bilgrami, Syed F.
    ACTA HAEMATOLOGICA, 2011, 126 (01) : 40 - 43
  • [46] Progressive multifocal leukoencephalopathy during rituximab maintenance after rituximab and bendamustine treatment for relapsed follicular lymphoma
    Marko Lucijanic
    Ozren Jaksic
    Annals of Hematology, 2020, 99 : 2191 - 2192
  • [47] Progressive multifocal leukoencephalopathy during rituximab maintenance after rituximab and bendamustine treatment for relapsed follicular lymphoma
    Lucijanic, Marko
    Jaksic, Ozren
    ANNALS OF HEMATOLOGY, 2020, 99 (09) : 2191 - 2192
  • [48] Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study
    Phillips, Tycel Jovelle
    Carlo-Stella, Carmelo
    Morschhauser, Franck
    Bachy, Emmanuel
    Crump, Michael
    Trneny, Marek
    Bartlett, Nancy L.
    Zaucha, Jan
    Wrobel, Tomasz
    Offner, Fritz
    Humphrey, Kathryn
    Relf, James
    de L'Etang, Audrey Filezac
    Carlile, David J.
    Byrne, Ben
    Qayum, Naseer
    Lundberg, Linda
    Dickinson, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (03)
  • [49] Ibrutinib, Bendamustine, Rituximab Combination for Relapsed and Refractory Aggressive B Cell Lymphoma - Interim Analysis of Phase II Clinical Trial
    Kedmi, Meirav
    Ribakovsy, Elena
    Benjamini, Ohad
    Schiby, Ginette
    Barshack, Iris
    Raskin, Stephen P.
    Eshet, Yael
    Mehr, Ramit
    Bitansky, Guy
    Nagler, Arnon
    Avigdor, Abraham
    BLOOD, 2018, 132
  • [50] A Phase II Study of Brentuximab Vedotin and Bendamustine for Relapsed/Refractory Follicular Lymphoma
    Kaleka, Guneet
    Moskoff, Benjamin
    Zafar, Aneeqa
    Esteghamat, Naseem S.
    Abedi, Mehrdad
    Socola, Francisco Andres
    Hoeg, Rasmus T.
    Tuscano, Joseph M.
    BLOOD, 2024, 144 : 6318 - 6319
12345